125Ⅰ Labeling of Recombinant Human Endostatin and Its Metabolism

Bei YOU,Biao LI,Yi-fan ZHANG,Gui-zhi YIN,Long ZHAO,Zhi-yong ZHANG,Lin LU,Jin-de YU,Zi-cheng YU,Cheng-mo ZHU
DOI: https://doi.org/10.3969/j.issn.1674-8115.2005.12.006
2005-01-01
Abstract:Objective To study the biological activity and in vivo pharmacokinetics of ~(125)I labeled recombinant human endostatin (~(125)I-rhEndo). Methods ~(125)I-rhEndo was prepared by small amount of iodogen with repeated labeling. Radiochemical purity (RP) was tested by paper chromatographic analysis. Biological activity of ~(125)I rhEndo was evaluated according to cell proliferation assays and cell affinity assays. And pharmacokinetic parameters of ~(125)I-rhEndo in the SD rats were also analyzed. Results ~(125)I-rhEndo was prepared by 0.5 μg iodogen labeling thrice with its radio purity reached (94.7±2.44)%. The labeling rate was 84%. Cell proliferation assays showed no significant difference between the ~(125)I-rhEndo and unlabeled rhEndo on inhibition of bFGF-induced ECV304 cell proliferation. In cell affinity assays ~(125)I-rhEndo could bind the endothelial cell surface receptors in compitition with unlabeled rhEndo. After intravenous injection with a single dose of 2 μg ~(125)I-rhEndo to rats, the plasma concentration-time curve fitted well to two-compartment model. The T_(1/2α)=(0.45±0.12) h, T_(1/2β)=(19.53±3.41) h, AUC=(484.57±137.99) ng·h·mL~(-1). Conclusion Small amount of iodogen repeated ~(125)I labeling assay did not influence the biological activity of rhEndo. After intravenous injection with a single dose of 2 μg ~(125)I-rhEndo to rats, its pharmacokinetic was in correspondence with two-compartment model with half life about 19 h.~(125)I labeling of rhEndo outlined the potential of this targeting agent for cancer imaging and therapy.
What problem does this paper attempt to address?